Venlafaxine. A review of its pharmacology and therapeutic potential in depression.
作者： Stephen M. Holliday , Paul Benfield
DOI: 10.2165/00003495-199549020-00010
关键词:
摘要: … of venlafaxine has also been demonstrated in in vivo models of depression. Venlafaxine has no … Venlafaxine exists as a racemic mixture of (−) and (+) enantiomers. The (−) enantiomer …
springer.com
sci-hub.se 参考文章(40)
Mendels J, Johnston R, Mattes J, Riesenberg R, EFFICACY AND SAFETY OF B.I.D. DOSES OF VENLAFAXINE IN A DOSE-RESPONSE STUDY Psychopharmacology Bulletin. ,vol. 29, pp. 169- 174 ,(1993)
Ram K Shrivastava, Cal Cohn, John Crowder, Jonathan Davidson, David Dunner, John Feighner, Ari Kiev, Roger Patrick, None, Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of Clinical Psychopharmacology. ,vol. 14, pp. 322- 329 ,(1994)
Karl Rickels, Laura A. Mandos, Edward Schweizer, John Feighner, Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. The Journal of Clinical Psychiatry. ,vol. 55, pp. 104- 108 ,(1994)
H. V. Semlitsch, P. Anderer, B. Saletu, G. A. Binder, K. A. Decker, Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in young healthy subjects International Clinical Psychopharmacology. ,vol. 8, pp. 155- 166 ,(1993) , 10.1097/00004850-199300830-00004
Eric A. Muth, John A. Moyer, J. Thomas Haskins, Terrance H. Andree, G. E. Morris Husbands, Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine Drug Development Research. ,vol. 23, pp. 191- 199 ,(1991) , 10.1002/DDR.430230210
C. Paul Wang, Stanley R. Howell, Joann Scatina, Samuel F. Sisenwine, The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality. ,vol. 4, pp. 84- 90 ,(1992) , 10.1002/CHIR.530040204
Karen J. Klamerus, Kathleen Moloney, Richard L. Rudolph, Samuel F. Sisenwine, William J. Jusko, Soong T. Chiang, Introduction of a Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O‐Desmethyl Metabolite The Journal of Clinical Pharmacology. ,vol. 32, pp. 716- 724 ,(1992) , 10.1002/J.1552-4604.1992.TB03875.X
C. Bolden-Watson, E. Richelson, Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes Life Sciences. ,vol. 52, pp. 1023- 1029 ,(1993) , 10.1016/0024-3205(93)90194-8
Michael A. Nader, William L. Woolverton, Evaluation of the discriminative stimulus effects of venlafaxine, a potential antidepressant, in rhesus monkeys Drug Development Research. ,vol. 25, pp. 75- 80 ,(1992) , 10.1002/DDR.430250108
LYNN A. CUNNINGHAM, RICHARD L. BORISON, JOHN S. CARMAN, GUY CHOUINARD, JOHN E. CROWDER, BRUCE I. DIAMOND, DANIEL E. FISCHER, EARL HEARST, A comparison of venlafaxine, trazodone, and placebo in major depression Journal of Clinical Psychopharmacology. ,vol. 14, pp. 99- 106 ,(1994) , 10.1097/00004714-199404000-00003